Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oculis Holding ( (OCS) ) has shared an announcement.
On May 11, 2026, Oculis Holding AG reported unaudited financial results for the three months ended March 31, 2026, filing a Form 6-K with the U.S. Securities and Exchange Commission that included interim financial statements and management’s discussion and analysis. The company reported total assets of CHF 243.99 million and equity of CHF 196.65 million, with substantial cash, cash equivalents and short-term financial assets supporting its operations, while continued research and development and general and administrative spending maintained the group in a loss-making but well-capitalized position.
The interim balance sheet showed current assets of CHF 227.04 million, driven mainly by CHF 64.56 million in cash and cash equivalents and CHF 157.47 million in short-term financial assets, underscoring a strong liquidity profile for ongoing clinical and corporate activities. Total liabilities rose to CHF 47.35 million, including higher warrant liabilities and trade payables, but the solid equity base and growing share premium signal continued investor support as Oculis advances its ophthalmic pipeline despite accumulated losses and negative operating income.
The most recent analyst rating on (OCS) stock is a Buy with a $68.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.
Spark’s Take on OCS Stock
According to Spark, TipRanks’ AI Analyst, OCS is a Neutral.
The score is primarily held back by persistent losses and cash burn with limited revenue visibility, partially offset by a strong, low-debt balance sheet. Technicals are mixed (longer-term support but weaker near-term momentum), and valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on OCS stock, click here.
More about Oculis Holding
Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on developing innovative ophthalmic therapies. The company targets eye diseases using novel drug delivery technologies and maintains a pipeline of clinical-stage candidates aimed at addressing unmet medical needs in global ophthalmology markets.
Average Trading Volume: 359,842
Technical Sentiment Signal: Buy
Current Market Cap: $1.87B
Find detailed analytics on OCS stock on TipRanks’ Stock Analysis page.